CCR2 Cytotoxicity Targeting Chimeras for Selective Antibody Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-based therapeutics suffer from bioavailability issues, high cost, thermal instability, and complex manufacturing, while small molecule therapeutics lack selectivity and cause off-target effects, necessitating improved therapeutic approaches for targeting pathogenic cells.
Innovation Solution
Development of heterobifunctional molecules, known as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs), which bind to a target cell-surface protein and an exogenous antibody, utilizing a divalent linker to enhance antibody-dependent cell cytotoxicity (ADCC) and deplete CCR2-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapeutics are used to target pathogenic cells, then selectivity and immune control are improved, but bioavailability, thermal stability, and manufacturing ease deteriorate
Solution Approach 1:
The patent divides the therapeutic function into two separate components: a small molecule CCR2-binding agent and a separate antibody. The small molecule handles target recognition and binding, while the antibody provides effector functions. This segmentation allows each component to be optimized independently for its specific function, improving manufacturability while maintaining selectivity.
Solution Approach 2:
The patent introduces an intermediary mechanism where the small molecule CCR2-binding agent acts as a bridge to recruit antibodies to the target cell surface. This intermediary approach allows the small molecule to guide the antibody to the correct target, combining the selectivity advantages of both small molecules and antibodies while avoiding their individual limitations.
2Ease of manufacture
If small molecule therapeutics are used for treatment, then affordability and stability are improved, but selectivity and off-target effects worsen
Solution Approach 1:
The patent merges the advantages of small molecules (affordability, stability) with the advantages of antibodies (selectivity, immune control) into a single therapeutic strategy. The small molecule CCR2-binding agent provides the affordability and stability, while the recruited antibody provides the selectivity and immune-mediated cytotoxicity, creating a synergistic combination that overcomes the limitations of either approach alone.
3Power
If heterobifunctional molecules are used to recruit antibodies, then ADCC enhancement is improved, but molecular complexity increases
Solution Approach 1:
The patent employs a self-service mechanism where the small molecule CCR2-binding agent autonomously recruits antibodies to the target cell surface through its binding to CCR2. The system uses the natural expression of CCR2 on target cells as a built-in recruitment signal, eliminating the need for complex engineered recruitment domains or additional recruitment molecules, thereby enhancing ADCC while limiting complexity increase.
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.